Gefitinib-Induced Hair Alterations: Figure 1

Gefitinib, an EGFR tyrosine kinase inhibitor used in anticancer therapy, was associated with hair alterations in a patient with non-small-cell lung cancer. After several months of treatment, the patient's scalp hair grew more slowly and became finer, more brittle, and curly, while eyelashes, eyebrows, and other facial hair remained unchanged. The exact cause of these hair changes was unclear, though it was suggested that EGFR inhibition in the skin might be responsible. The study highlighted the need for further research to understand this phenomenon, as there were no established evidence-based management strategies for such hair alterations.